CG Oncology (NASDAQ:CGON) Trading Up 7.9%

CG Oncology, Inc. (NASDAQ:CGON) shares shot up 7.9% during trading on Tuesday . The stock traded as high as $36.67 and last traded at $36.19. 150,264 shares traded hands during trading, a decline of 76% from the average session volume of 621,993 shares. The stock had previously closed at $33.54.

Analyst Ratings Changes

CGON has been the topic of a number of research analyst reports. Cantor Fitzgerald assumed coverage on shares of CG Oncology in a research report on Tuesday, February 20th. They set an “overweight” rating and a $75.00 price objective on the stock. The Goldman Sachs Group assumed coverage on CG Oncology in a research report on Tuesday, February 20th. They set a “neutral” rating and a $42.00 price objective for the company. Morgan Stanley began coverage on CG Oncology in a research note on Tuesday, February 20th. They set an “overweight” rating and a $55.00 price target for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $75.00 price objective on shares of CG Oncology in a research note on Thursday, April 4th.

CG Oncology Stock Up 0.4 %

The company’s 50 day moving average is $40.54.

Insiders Place Their Bets

In other CG Oncology news, Director Hong Fang Song purchased 263,157 shares of the business’s stock in a transaction on Monday, January 29th. The stock was acquired at an average price of $19.00 per share, for a total transaction of $4,999,983.00. Following the purchase, the director now owns 613,928 shares of the company’s stock, valued at approximately $11,664,632. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, major shareholder Decheng Capital Global Life Sc bought 400,000 shares of the stock in a transaction dated Monday, January 29th. The shares were purchased at an average price of $19.00 per share, with a total value of $7,600,000.00. Following the completion of the acquisition, the insider now owns 400,000 shares of the company’s stock, valued at $7,600,000. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Hong Fang Song bought 263,157 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The shares were bought at an average price of $19.00 per share, with a total value of $4,999,983.00. Following the transaction, the director now owns 613,928 shares of the company’s stock, valued at approximately $11,664,632. The disclosure for this purchase can be found here. Insiders bought a total of 666,472 shares of company stock worth $12,662,968 over the last three months.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.